Jae Seuk Park

Jae Seuk Park

Auto-generated profile, based on publicly available information

Jae Seuk Park

Division of Pulmonary Medicine, Department of Internal Medicine, Dankook University College of Medicine , Cheonan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2019 in Trials
Verified
Journal Article
Open access
PDF file
MLMyungsun Lee
Myungsun Lee
JMJeongha Mok
Jeongha Mok
DKDeog Kyeom Kim
Deog Kyeom Kim
TSTae Sun Shim
Tae Sun Shim
WKWon-Jung Koh
Won-Jung Koh
JYJae-Joon Yim
Jae-Joon Yim
Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain unsatisfactory, and long-term use of second-line anti-TB drugs is accompanied by the frequent occurrence of adverse events, low treatment compliance, and high costs. The development of new efficient regimens with shorter treatment durations for MDR-TB will solve these issues and improve treatment outcomes. This study is a phase II/III, multicenter, randomized, open-label clinical trial of non-inferiority design comparing a new regimen to the World Health Organization-endorsed conventional regimen for fluoroquinolone-sensitive MDR-TB. The control arm uses a conventional treatment regimen with second-line drugs including injectables for 20–24 months. The investigational arm uses a new shorter regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9 or 12 months depending on time to sputum culture conversion. The primary outcome is the treatment success rate at 24 months after treatment initiation. Secondary outcomes include time to sputum culture conversion on liquid and solid media, proportions of sputum culture conversion on liquid media after 2 and 6 months of treatment, treatment success rate according to pyrazinamide resistance, and occurrence of adverse events grade 3 and above as evaluated by the Common Terminology Criteria for Adverse Events. Based on an α = 0.025 level of significance (one-sided test), a power of 80%, and a < 10% difference in treatment success rate between the control and investigational arms (80% vs. 70%) when the anticipated actual success rate in the treatment group is assumed to be 90%, the number of participants needed per arm to show non-inferiority of the investigational regimen was calculated as 48. Additionally, assuming the proportion of fluoroquinolone-susceptible MDR-TB among participants as 50%, and 5% loss to follow-up, the number of participants is calculated as N/( 0.50 × 0.95), resulting in 102 persons per group (204 in total). This trial will reveal the effectiveness and safety of a new shorter regimen comprising four oral drugs, including delamanid, linezolid, levofloxacin, and pyrazinamide, for the treatment of fluoroquinolone-sensitive MDR-TB. Results from this trial will provide evidence for adopting a shorter and more convenient treatment regimen for MDR-TB. ClincalTrials.gov, NCT02619994 . Registered on 2 December 2015.

22 August 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JMJinsoo Min
Jinsoo Min
JKJu Sang Kim
Ju Sang Kim
HKHyung Woo Kim
Hyung Woo Kim
ASAh Young Shin
Ah Young Shin
HKHyeon-Kyoung Koo
Hyeon-Kyoung Koo
JPJae Seuk Park
Jae Seuk Park
Although the incidence of tuberculosis (TB) has decreased in South Korea, the mortality rate remains high. TB mortality is a key indicator for TB control interventions. The purpose of this study was to assess early and TB-related mortality during anti-TB treatment and describe the associated clinical characteristics. A multicenter cross-sectional study was performed across South Korea. Patients with pulmonary TB who died during anti-TB treatment and whose records were submitted to the national TB surveillance system between 2015 and 2017 were enrolled. All TB deaths were categorized based on cause (TB-related or non-TB-related) and timing (early or late). We identified statistical associations using the frequency table, chi-square test, and binary logistic regression. Of 5595 notifiable mortality cases, 3735 patients with pulmonary TB were included in the analysis. There were 2541 (68.0%) male patients, and 2935 (78.6%) mortality cases were observed in patients older than 65 years. There were 944 (25.3%) cases of TB-related death and 2545 (68.1%) cases of early death. Of all cases, 187 (5.0%) patients were diagnosed post-mortem and 38 (1.0%) patients died on the first day of treatment. Low body mass index (adjusted odds ratio (aOR) = 1.26; 95% confidence interval (CI) = 1.08–1.48), no reported illness (aOR = 1.36; 95% CI = 1.10–1.68), bilateral disease on chest X-ray (aOR = 1.30; 95% CI = 1.11–1.52), and positive acid-fast bacilli smear result (aOR = 1.30; 95% CI = 1.11–1.52) were significantly associated with early death, as well as TB-related death. Acute respiratory failure was the most common mode of non-TB-related death. Malignancy was associated with both late (aOR = 0.71; 95% CI = 0.59–0.89) and non-TB-related (aOR = 0.35; 95% CI = 0.26–0.46) death. A high proportion of TB death was observed in elderly patients and attributed to non-TB-related causes. Many TB-related deaths occurred during the intensive phase, particularly within the first month. Further studies identifying risk factors for different causes of TB death at different phases of anti-TB treatment are warranted for early targeted intervention in order to reduce TB mortality.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JMJinsoo Min
Jinsoo Min
HKHyung Woo Kim
Hyung Woo Kim
HKHyeon-Kyoung Koo
Hyeon-Kyoung Koo
YKYousang Ko
Yousang Ko
JOJee Youn Oh
Jee Youn Oh
JKJu Sang Kim
Ju Sang Kim
Min J, et al. J Korean Med Sci. 2020 Sep;35(43):e388. https://doi.org/10.3346/jkms.2020.35.e388

31 January 2010 in Tuberculosis
Verified
Journal Article
Closed access
SKSang-Heon Kim
Sang-Heon Kim
HYHo Joo Yoon
Ho Joo Yoon
YSYouhwan Shin
Youhwan Shin
SPSung Soo Park
Sung Soo Park
YKYoun-Seup Kim
Youn-Seup Kim
YJYoung Koo Jee
Young Koo Jee

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
SPSunghoon Park
Sunghoon Park
SLSun Hwa Lee
Sun Hwa Lee
KSKi-Hyun Seo
Ki-Hyun Seo
KSKyeong-Cheol Shin
Kyeong-Cheol Shin
YPYong Bum Park
Yong Bum Park
KJKi-Suck Jung
Ki-Suck Jung
Park S, et al. J Korean Med Sci. 2014 Sep;29(9):1232-1239. https://doi.org/10.3346/jkms.2014.29.9.1232

1 January 2022 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JMJinsoo Min
Jinsoo Min
YKYousang Ko
Yousang Ko
HKHyung Woo Kim
Hyung Woo Kim
HKHyeon-Kyoung Koo
Hyeon-Kyoung Koo
JOJee Youn Oh
Jee Youn Oh
JKJu Sang Kim
Ju Sang Kim
Min J, et al. J Korean Med Sci. 2021 Dec;37(3):e20. https://doi.org/10.3346/jkms.2022.37.e20